V Blair Journigan1, Willma E Polgar2, Taline V Khroyan2, Nurulain T Zaveri3. 1. Astraea Therapeutics, LLC., 320 Logue Avenue, Mountain View, CA 94043, United States. 2. SRI International, Biosciences Division, 333 Ravenswood Avenue, Menlo Park, CA 94025, United States. 3. Astraea Therapeutics, LLC., 320 Logue Avenue, Mountain View, CA 94043, United States. Electronic address: nurulain@astraeatherapeutics.com.
Abstract
The nociceptin opioid receptor (NOP) and its endogenous peptide ligand nociceptin/orphanin FQ have been shown to modulate the pharmacological effects of the classical opioid receptor system. Suppression of opioid-induced reward associated with mu-opioid receptor (MOP)-mediated analgesia, without decreasing anti-nociceptive efficacy, can potentially be achieved with NOP agonists having bifunctional agonist activity at MOP, to afford 'non-addicting' analgesics. In Part II of this series, we describe a continuing structure-activity relationship (SAR) study of the NOP-selective piperidin-4-yl-1,3-dihydroindol-2-one scaffold, to obtain bifunctional activity at MOP, and a suitable ratio of NOP/MOP agonist activity that produces a non-addicting analgesic profile. The SAR reported here is focused on the influence of various piperidine nitrogen aromatic substituents on the ratio of binding affinity and intrinsic activity at both the NOP and MOP receptors.
The nociceptin opioid receptor (n class="Gene">NOP) and its endogenous peptide ligand nociceptin/orphanin FQ have been shown to modulate the pharmacological effects of the classical opioid receptor system. Suppression of opioid-induced reward associated with mu-opioid receptor (MOP)-mediated analgesia, without decreasing anti-nociceptive efficacy, can potentially be achieved with NOP agonists having bifunctional agonist activity at MOP, to afford 'non-addicting' analgesics. In Part II of this series, we describe a continuing structure-activity relationship (SAR) study of the NOP-selective piperidin-4-yl-1,3-dihydroindol-2-one scaffold, to obtain bifunctional activity at MOP, and a suitable ratio of NOP/MOP agonist activity that produces a non-addicting analgesic profile. The SAR reported here is focused on the influence of various piperidinenitrogenaromatic substituents on the ratio of binding affinity and intrinsic activity at both the NOP and MOP receptors.
Authors: L Toll; I P Berzetei-Gurske; W E Polgar; S R Brandt; I D Adapa; L Rodriguez; R W Schwartz; D Haggart; A O'Brien; A White; J M Kennedy; K Craymer; L Farrington; J S Auh Journal: NIDA Res Monogr Date: 1998-03
Authors: Henry I Mosberg; Larisa Yeomans; Aubrie A Harland; Aaron M Bender; Katarzyna Sobczyk-Kojiro; Jessica P Anand; Mary J Clark; Emily M Jutkiewicz; John R Traynor Journal: J Med Chem Date: 2013-02-27 Impact factor: 7.446
Authors: Nurulain T Zaveri; Faming Jiang; Cris Olsen; Willma E Polgar; Lawrence Toll Journal: Bioorg Med Chem Lett Date: 2013-04-04 Impact factor: 2.823
Authors: J Wichmann; G Adam; S Röver; M Hennig; M Scalone; A M Cesura; F M Dautzenberg; F Jenck Journal: Eur J Med Chem Date: 2000-09 Impact factor: 6.514
Authors: Huiping Ding; Norikazu Kiguchi; Dennis Yasuda; Pankaj R Daga; Willma E Polgar; James J Lu; Paul W Czoty; Shiroh Kishioka; Nurulain T Zaveri; Mei-Chuan Ko Journal: Sci Transl Med Date: 2018-08-29 Impact factor: 17.956
Authors: Karel Guillemyn; Joanna Starnowska; Camille Lagard; Jolanta Dyniewicz; Ewelina Rojewska; Joanna Mika; Nga N Chung; Valérie Utard; Piotr Kosson; Andrzej W Lipkowski; Lucie Chevillard; Pol Arranz-Gibert; Meritxell Teixidó; Bruno Megarbane; Dirk Tourwé; Frédéric Simonin; Barbara Przewlocka; Peter W Schiller; Steven Ballet Journal: J Med Chem Date: 2016-04-14 Impact factor: 7.446
Authors: Federica Ferrari; Davide Malfacini; Blair V Journigan; Mark F Bird; Claudio Trapella; Remo Guerrini; David G Lambert; Girolamo Calo'; Nurulain T Zaveri Journal: Pharmacol Res Perspect Date: 2017-08